Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer β¦ (NCT07302126) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy
China40 participantsStarted 2025-12-11
Plain-language summary
Research Objective and Principle: To evaluate the effectiveness of Bergmann enema in preventing acute radiation-induced rectal injury in patients with rectal cancer, thereby providing a basis for treatment options for potential radiation-induced rectal injury patients, aiming for adoption by international guidelines.
Primary Objective: Incidence of grade 2 or higher radiation-induced rectal injury.
Secondary Objectives: Severity of radiation-induced rectal injury, completion rate of short-course radiotherapy, safety of Bergmann enema, quality of life, pathological complete response (pCR) rate.
Study Design: Prospective, single-center, single-arm study.
Study Population and Expected Enrollment: Patients with rectal cancer undergoing short-course radiotherapy, expecting to enroll 40 patients.
Trial Duration: From December 2025 to December 2026.
Intervention: Patients will receive Bergmann enema (30 ml) once daily from the start of radiotherapy until the 10th day after the end of radiotherapy.
Statistical Hypothesis: Based on previous reports, the incidence of acute radiation-induced rectal injury is 80%, and it is expected that Bergmann enema preventive treatment can reduce it to 50%. The sample size was estimated using a formula designed to calculate single-group rate, with a set at 0.05 and a power of 80%. The study aimed to enroll at least 36 patients. Considering a dropout rate of 10%, at least 40 patients need to be included.
Who can participate
Age range18 Years β 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
β. Aged 18 to 75 years, regardless of gender;
β. Fully understand this study and voluntarily sign the informed consent form, able to comply with the study protocol and complete all trial procedures;
β. Patients with pathologically confirmed mid-lower rectal cancer;
β. Undergoing short-course pelvic radiotherapy (total dose of 25-35Gy in 5.0-7.0 fractions over 5 consecutinve days);
β. Eastern Cooperative Oncology Group (ECOG) score of 0-1, with an expected survival time of more than 6 months;
β. Assessment by the attending physician and researcher indicates that vital organ function can tolerate the treatment risks.
Exclusion criteria
β. Severe comorbidities, including uncontrolled stable medical diseases after treatment, or a history of neurological or psychiatric disorders (such as dementia or epilepsy), making them unsuitable for radiotherapy;
β. Patients who have received pelvic radiotherapy;
What they're measuring
1
Incidence of grade 2 or higher radiation-induced rectal injury
Timeframe: 3 months
Trial details
NCT IDNCT07302126
SponsorSixth Affiliated Hospital, Sun Yat-sen University